OptymEdge has appointed Amy Del Medico as senior director of project delivery and transformation to lead the scale-up and global roll-out of Acuvera, an integrated AI-powered suite of technology solutions developed for ophthalmology clinical trials. The platform will be soft-launched at the American Academy of Ophthalmology (AAO) event in Orlando next month.

Del Medico brings more than 20 years of experience in clinical trials across contract research organisations (CROs) and biopharma innovators. She spent 17 years at IQVIA, where she served as director of the centre of excellence for ophthalmology, and most recently was head of clinical operations at Vial.

Ophthalmology clinical trials are undergoing rapid digital transformation, and OptymEdge aims to advance the integration of visual function data capture with advanced imaging, AI, and analytics. The Acuvera platform connects sites, sponsors and CROs in real time, standardising workflows and enabling faster access to imaging and clinical data. The company said this improves data consistency and decision-making efficiency across studies.

“It’s a really exciting time for the business as we lead the digital transformation of ophthalmology clinical trials,” said Del Medico. “My focus will be on driving the global roll-out and adoption of the Acuvera suite, which includes digital solutions for certification, data capture and ophthalmic image reading. Together, these new tools will enhance data quality and trial efficiency, and my goal is to ensure our delivery team can apply these new technologies and tools while bringing measurable impact to our customers and patients.”

Acuvera has been designed as a bespoke platform that combines therapeutic expertise with automation, risk-based quality management (RBQM) insights, and endpoint-specific intelligence. It enables visual function data capture, imaging and certification within a unified system.

Del Medico added: “By unifying these critical workflows within a single, secure platform, sponsors and CROs can reduce operational complexity, improve endpoint quality, and accelerate study timelines. With many trials now looking to Asia and its large recruitment base, the key challenge is integrating processes across regions – particularly given the diversity of sites and evolving regulatory landscapes. Acuvera will play a crucial role in harmonising data, ensuring compliance, and enabling seamless collaboration across regions.”

OptymEdge said the platform has been developed to meet the growing demand for precision and automation in ophthalmology research, with scalability designed for multi-region trials. The company’s focus is on enabling consistent, high-quality imaging and data collection standards that support faster, more reliable outcomes for sponsors and patients alike.